578 related articles for article (PubMed ID: 27094312)
21. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
Law ST; Lee MK; Li KK; Mok CK
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
[TBL] [Abstract][Full Text] [Related]
22. Observation of combined/optimized therapy of Lamivudine and Adefovir Dipivoxyl for hepatitis B-induced decompensated cirrhosis with baseline HBV DNA>1,000 IU/mL.
Zhang D; Zhao G; Li L; Li Z
Acta Gastroenterol Belg; 2017; 80(1):9-13. PubMed ID: 29364091
[TBL] [Abstract][Full Text] [Related]
23. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study.
Tsai MC; Chen CH; Hung CH; Lee CM; Chiu KW; Wang JH; Lu SN; Tseng PL; Chang KC; Yen YH; Hu TH
Clin Microbiol Infect; 2014 Feb; 20(2):O90-O100. PubMed ID: 23659493
[TBL] [Abstract][Full Text] [Related]
24. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
[TBL] [Abstract][Full Text] [Related]
25. A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B.
Lee KJ; Choe BH; Choe JY; Kim JY; Jeong IS; Kim JW; Yang HR; Chang JY; Kim KM; Moon JS; Ko JS
J Korean Med Sci; 2018 Feb; 33(8):e63. PubMed ID: 29441755
[TBL] [Abstract][Full Text] [Related]
26. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Jeon HJ; Jung SW; Park NH; Yang Y; Noh JH; Ahn JS; Kim HR; Lee JH; Shin JW
Clin Mol Hepatol; 2017 Sep; 23(3):230-238. PubMed ID: 28669175
[TBL] [Abstract][Full Text] [Related]
28. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
Kim HJ; Park SK; Yang HJ; Jung YS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Choi KY
Clin Mol Hepatol; 2016 Sep; 22(3):350-358. PubMed ID: 27729626
[TBL] [Abstract][Full Text] [Related]
30. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
Kim DH; Choi JW; Seo JH; Cho YS; Won SY; Park BK; Jeon HH; Shin SY; Lee CK
Yonsei Med J; 2017 May; 58(3):552-556. PubMed ID: 28332360
[TBL] [Abstract][Full Text] [Related]
31. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
Wang GL; Liu Y; Qiu P; Zhou SF; Xu LF; Wen P; Wen JB; Xiao XZ
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):866-72. PubMed ID: 27010143
[TBL] [Abstract][Full Text] [Related]
33. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
34. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
35. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
36. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
Son CY; Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
Liver Int; 2012 Aug; 32(7):1179-85. PubMed ID: 22452737
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
38. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
40. Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study.
Du QW; Ding JG; Sun QF; Hong L; Cai FJ; Zhou QQ; Wu YH; Fu RQ
Med Sci Monit; 2013 Sep; 19():751-6. PubMed ID: 24019010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
